What 9 Analyst Ratings Have To Say About Mind Medicine
Portfolio Pulse from Benzinga Insights
Analysts have provided a mix of bullish and somewhat bullish ratings for Mind Medicine (NASDAQ:MNMD) in the last quarter, with no bearish or indifferent ratings. The average 12-month price target for the stock is $26.33, a decrease of 34.18% from the previous average of $40.00.
August 04, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mind Medicine has received positive ratings from analysts, but the average 12-month price target has decreased, indicating a potential short-term decrease in stock price.
Analysts' ratings are generally a good indicator of a stock's future performance. In this case, while the ratings are positive, the decrease in the average 12-month price target suggests that analysts expect the stock price to decrease in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100